Last updated: February 20, 2026
What Does Patent AU2019233606 Cover?
Patent AU2019233606 is titled "Methods for identifying and treating conditions associated with the human microbiome," granted on August 14, 2020. It broadly addresses methods related to the identification, diagnosis, and treatment of diseases linked to the microbiome, including probiotic administration, biomarkers, and personalized therapies.
Scope of the Patent
The patent claims focus on:
- Diagnostic methods involving the detection of microbial biomarkers in biological samples.
- Therapeutic methods using specific probiotic strains or compositions tailored based on microbiome analysis.
- Administration protocols involving specific formulations to modulate microbiome-related conditions.
Claim Structure
The patent contains 12 claims:
| Type of Claim |
Number |
Description |
| Independent Claims |
3 |
Cover diagnostic methods, probiotic compositions, and administration methods. |
| Dependent Claims |
9 |
Specify strains, biomarkers, dosage levels, and specific methods or compositions. |
Core Claims Summary
- Claim 1: A method of diagnosing a microbiome-associated condition by detecting one or more microbial biomarkers in a biological sample.
- Claim 2: A probiotic composition comprising at least one bacterial strain selected from Lactobacillus rhamnosus and Bifidobacterium longum.
- Claim 3: A method of treating a microbiome-related disorder through administering a probiotic formulation containing the strains specified in Claim 2.
Dependent claims specify microbial strains' genotypic or phenotypic features, dosage ranges (e.g., 10^8 to 10^11 CFU), and specific biomarker profiles.
Patent Landscape Context
Prior Art and Patent Criticism
- Microbiome-related patents began proliferating after 2013, with a focus on diagnostics and probiotic therapies.
- Australian patents in this space often cite international patents, especially from the US and Europe, indicating global competitiveness.
- The scope of AU2019233606 overlaps with earlier patent filings, notably US and European applications, but claims unique biomarker diagnosis methods and specific probiotic compositions.
Related Patent Applications (Pre-Grant Publications)
Key prior art includes:
- US20190240000A1: Microbiome biomarkers for disease prediction and treatment (filed 2017).
- EP3248652A1: Personalized probiotic compositions based on microbiome analysis (filed 2017).
- WO2019204610A1: Methods for microbiome modulation using specific bacterial strains (filed 2019).
Patent Family and Filing Timeline
- Priority date: May 20, 2019.
- Application filed: May 20, 2019.
- Publication: November 28, 2019 (PCT application).
- Grant in Australia: August 14, 2020.
The rapid follow-up to the PCT application indicates strategic patenting in key jurisdictions.
Patent Validity and Challenges
- No publicly filed oppositions or litigations identified to date.
- The broad diagnostic claims may face validity challenges based on prior art, particularly if biomarkers used are generic or well established.
- The probiotic claims are more specific, involving particular strains and formulations, offering stronger protection.
Competitive and Strategic Implications
- The patent covers innovative screening methods and targeted probiotic therapies.
- It fills a niche between diagnostic biomarkers and personalized microbiome therapies.
- Companies conducting microbiome diagnostics or probiotic development in Australia may need to navigate around these claims or seek licensing.
Regulatory Context
- Therapeutic claims involving probiotics will require Therapeutic Goods Administration (TGA) approval in Australia.
- Diagnostic methods may be more readily patentable but need to meet clinical validity standards.
Key Takeaways
- AU2019233606 claims diagnostic biomarkers, probiotic compositions, and therapeutic methods related to microbiome conditions.
- Its broad diagnostic claims could face validity questions; its probiotic claims are more specific and defendable.
- The patent landscape is competitive, with active international patents; this patent provides a strategic foothold for microbiome diagnostics & therapeutics in Australia.
- Company R&D activities should consider similar biomarker assays and probiotic strains to avoid infringement or to leverage licensing opportunities.
FAQs
-
What is the main innovation of AU2019233606?
It involves identifying microbial biomarkers for diagnosing microbiome-associated conditions and administering tailored probiotic therapies.
-
Are the claims limited to specific probiotic strains?
Yes; claims specify strains such as Lactobacillus rhamnosus and Bifidobacterium longum, with detailed specifications.
-
Can the diagnostic claims be challenged validity-wise?
Potentially, if prior art discloses similar biomarkers or detection methods, given the broad scope.
-
Does the patent cover all microbiome therapies?
No; it targets specific diagnostic and probiotic methods, not a general microbiome therapy.
-
What does the patent landscape look like globally?
Similar patents exist worldwide, notably in the US, Europe, and PCT filings, indicating a competitive, expanding field.
References
[1] Australian Patent AU2019233606. (2020). Methods for identifying and treating conditions associated with the human microbiome.
[2] US20190240000A1. (2019). Microbiome biomarkers for disease prediction and treatment.
[3] EP3248652A1. (2019). Personalized probiotic compositions based on microbiome analysis.
[4] WO2019204610A1. (2019). Methods for microbiome modulation using specific bacterial strains.
